Evidence map›Paper›PMID 42728593›Full record

ReviewOrphanet journal of rare diseases2026

Patient pathways for rare liver diseases: a European template developed by ERN RARE-LIVER.

Sarah Raevens, Renée Duijzer, Andreea Fodor, Matt Bolz Johnson, Nagham Issa, Sophie Pénisson, Samir Patel, Alice Bertolini, Carmen A J Teemer, Clemence Ramier and 7 more

Abstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sarah RaevensHepatology Research Unit, Department of Internal Medicine and Pediatrics, Liver Research Center, Ghent University, Ghent, Belgium.
Renée DuijzerDepartment of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands.
Andreea Fodor"Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Matt Bolz JohnsonEURORDIS - Rare Diseases Europe, Paris, France.
Nagham IssaDepartment of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Sophie PénissonAMVF French Patient's Association for Vascular Liver Diseases, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, Clichy, France.
Samir PatelAMVF French Patient's Association for Vascular Liver Diseases, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, Clichy, France.
Alice BertoliniGastroenterology and Multivisceral Transplant Unit, Padova University Hospital, Padova, Italy.
Carmen A J TeemerPKD Familiäre Zystennieren e.V., Hamburg, Germany.
Clemence RamierAix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.
Laure ElkriefService d'Hépato-Gastroentérologie, Hôpital Trousseau, CHRU de Tours, Tours, France.
Marco SenzoloGastroenterology and Multivisceral Transplant Unit, Padova University Hospital, Padova, Italy.
Virginia Hernandez-GeaBarcelona Hepatic Hemodynamics Laboratory, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBEREHD (Centro de Investigacion Biomedica en Red Enfermedades Hepaticas y Digestivas) University of Barcelona, Barcelona, 08036, Spain.
Ansgar W LohseDepartment of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Bogdan Procopet"Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Joost P H DrenthDepartment of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Aurélie PlessierService d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, Centre de Recherche sur l'inflammation, Inserm, UMR 1149, Université de Paris, AP-HP, Hôpital Beaujon, 100 Bd du Général Leclerc, Clichy, Paris, 92110, France. aurelie.plessier@aphp.fr.

Funding

Research Foundation - Flanders (FWO) 1802624N
6 · The paper itself

Abstract

backgroundRare liver diseases are associated with diagnostic delay, fragmented care, inconsistent management, and limited patient support. Patient pathways may help address these challenges by translating clinical guidance and patient priorities into practical, coordinated care processes. MAIN BODY: This manuscript presents a European template for developing patient-centred pathways for rare liver diseases within ERN RARE-LIVER. The template was developed through multidisciplinary collaboration involving hepatologists, specialist nurses, patient representatives, patient organisations, and EURORDIS, and was informed by clinical guidance, patient-journey principles, and iterative expert and patient review. The proposed framework follows four phases of the patient journey: pre-diagnosis, diagnosis, management, and long-term follow-up. It includes disease-specific sections, educational resources, frequently asked questions, and "10 key questions" to support shared decision-making. Pathways for non-cirrhotic portal vein thrombosis, polycystic liver disease, and portosinusoidal vascular disorder illustrate the practical application of the template.

conclusionThis European template provides a practical, adaptable framework aimed at supporting harmonised, multidisciplinary, and patient-centred care for rare liver diseases across European healthcare settings. Future work should evaluate implementation, usability, and impact on care coordination and patient experience.

Indexed as

Liver DiseasesRare DiseasesEuropeHumansPatient-Centered CareMultidisciplinary carePatient empowermentPatient pathwayRare liver disease

Identifiers

PMID42728593
PMCPMC13570500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.